Patent · US Active

Glycotargeting therapeutics

US10821157B2 · kind B2 · utility

15Cited by

121References

26Claims

0Family size

Assignees

Anokion SA · CH
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) · CH

Inventors

Jeffrey A. Hubbell · Austin, US
Stephane Kontos · Ecublens, CH
Kristen Marie Lorentz · Cambridge, US
David Scott Wilson · Redwood City, US
Shuning Gai · Gland, CH

Key dates

Filing date	Feb 20, 2015
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Jun 27, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/01
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.